Phase 2 trial in 112 patients with active psoriatic arthritis: ACR20 at week 12 was 47.4% with vunakizumab 120 mg and 59.5% with 240 mg vs 21.6% with placebo (P = 0.02; P = 0.001); adverse events were similar across groups.
RCTn = 112
Xue et al. Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 study